| Market Capitalization (Millions $) |
0 |
| Shares
Outstanding (Millions) |
4 |
| Employees |
47 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-35 |
| Cash Flow (TTM) (Millions $) |
5 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Effector Therapeutics Inc is a biopharmaceutical company that focuses on the development of novel cancer treatments. The company is dedicated to discovering and developing small molecule drugs that can target specific cellular pathways involved in tumor growth and progression.
Effector Therapeutics utilizes a unique approach called selective translation modulation (STM) to identify and develop potential therapies. STM involves targeting specific RNA translation factors that are critical for the synthesis of proteins involved in cancer cell survival and proliferation.
The company's pipeline includes several candidates that are currently in different stages of preclinical and clinical development. Their lead candidate, eFT508, is being evaluated in multiple clinical trials for the treatment of various types of solid tumors and lymphomas.
Effector Therapeutics has collaborations and partnerships with leading academic institutions and pharmaceutical companies in order to leverage their expertise and resources. They aim to bring innovative cancer therapies to patients in need and improve overall treatment outcomes.
Company Address: 142 North Cedros Avenue Solana Beach 92075 CA
Company Phone Number: 925-8215 Stock Exchange / Ticker: NASDAQ EFTR
|
0.000%
0.83%